A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients.

Trial Profile

A Phase III double blind, randomised, placebo-controlled study of the efficacy, safety and tolerability of idebenone in the treatment of Friedreich's Ataxia patients.

Completed
Phase of Trial: Phase III

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Idebenone (Primary)
  • Indications Friedreich's ataxia
  • Focus Registrational; Therapeutic Use
  • Acronyms MICONOS
  • Sponsors Santhera Pharmaceuticals
  • Most Recent Events

    • 17 May 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top